Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Payables (2016 - 2025)

Firefly Neuroscience has reported Payables over the past 15 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Payables at $1.3 million for Q4 2025, down 25.83% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 25.83% YoY), and the annual figure for FY2025 was $1.3 million, down 25.83%.
  • Payables for Q4 2025 was $1.3 million at Firefly Neuroscience, roughly flat from $1.3 million in the prior quarter.
  • Over the last five years, Payables for AIFF hit a ceiling of $2.3 million in Q2 2021 and a floor of $227560.0 in Q3 2022.
  • Median Payables over the past 5 years was $907825.0 (2023), compared with a mean of $1.1 million.
  • Biggest five-year swings in Payables: surged 1301.4% in 2021 and later crashed 86.8% in 2022.
  • Firefly Neuroscience's Payables stood at $650499.0 in 2021, then dropped by 11.79% to $573789.0 in 2022, then rose by 9.8% to $630000.0 in 2023, then surged by 188.25% to $1.8 million in 2024, then dropped by 25.83% to $1.3 million in 2025.
  • The last three reported values for Payables were $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.